Ig Vena (Human Normal Immunoglobulin (Iv))

Ig Vena, a human normal immunoglobulin, provides passive immunity for disorders involving antibody deficiency or immune dysregulation.

• Primary immunodeficiency diseases: restores deficient IgG levels to reduce infection frequency.
• Secondary immunodeficiency: supplements antibodies in patients with acquired immune deficits, such as after chemotherapy.
• Idiopathic thrombocytopenic purpura: modulates immune response to increase platelet count.
• Kawasaki disease: reduces inflammation and coronary artery complications in the acute phase.
• Chronic inflammatory demyelinating polyneuropathy: attenuates autoimmune attack on peripheral nerves.

• Human normal immunoglobulin consists of pooled IgG antibodies derived from healthy donors. After intravenous infusion, the IgG distributes in the vascular and extravascular compartments, providing immediate passive immunity by neutralizing pathogens and toxins. It also engages Fc receptors on immune cells, modulating complement activation, cytokine release, and autoantibody production, thereby restoring immune homeostasis in deficient or dysregulated states.

Ig Vena may be associated with infusion‑related reactions and other adverse events.

Common Side Effects

• Headache: mild to moderate pain often occurring during or shortly after infusion.
• Fever and chills: transient rise in body temperature and shivering.
• Nausea: occasional upset stomach or feeling of queasiness.
• Fatigue: temporary tiredness following administration.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction requiring immediate medical attention.
• Thromboembolic events: clot formation that can affect veins or arteries.
• Renal failure: impaired kidney function, especially with high infusion volumes.
• Aseptic meningitis: inflammation of the meninges without infection.

When using Ig Vena, clinicians should observe several safety measures.

• Screen for IgA deficiency: patients with anti‑IgA antibodies may develop severe reactions.
• Monitor renal function: high‑volume infusions can stress kidneys.
• Assess thrombotic risk: consider prophylaxis in patients with known risk factors.
• Avoid use in patients with known hypersensitivity to immunoglobulin products.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ig Vena can interact with several medications; awareness of the level of interaction helps guide monitoring.

Major Interactions (Avoid)

• Live vaccines: concurrent use may reduce vaccine efficacy and increase infection risk.
• Cytotoxic chemotherapy: may heighten renal toxicity when combined.
• Anticoagulants: can potentiate bleeding risk due to volume load.

Moderate Interactions (Monitor Closely)

• Diuretics: monitor fluid balance and electrolytes during infusion.
• ACE inhibitors: watch for hypotension, especially with rapid infusion rates.
• Rituximab: may alter immunoglobulin levels and affect therapeutic response.